Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096629 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Kidney Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00096629: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00096629 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096629, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
Interventions
- BIOLOGICAL human prostate-specific membrane antigen plasmid DNA vaccine
- BIOLOGICAL mouse prostate-specific membrane antigen plasmid DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
What the finished NCT00096629 record still lists
NCT00096629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which human prostate-specific membrane antigen plasmid DNA vaccine is the first listed.
NCT00096629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096629 about?
NCT00096629 is a clinical study titled "Vaccine Therapy in Treating Patients With Kidney Cancer". RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
What is the current status of trial NCT00096629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT00096629?
The interventions under investigation include: human prostate-specific membrane antigen plasmid DNA vaccine (BIOLOGICAL), mouse prostate-specific membrane antigen plasmid DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00096629?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096629's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia